Oragenics (OGEN) Return on Capital Employed (2011 - 2023)
Oragenics' (OGEN) quarterly Return on Capital Employed came in at 451.05% in Q4 2023, down 35027.0% YoY from N/an in Q4 2022, and down 193.83% on a QoQ basis from 153.51% in Q3 2023.
Oragenics (OGEN) Return on Capital Employed (2011 - 2023) Analysis & Trends
Oragenics (OGEN) has 13 years of Return on Capital Employed data on file, last reported at 451.05% in Q4 2023.
- Quarterly Return on Capital Employed fell 35027.0% year-over-year to 451.05% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 451.05% (down 35027.0% YoY) and the FY2023 annual result came in at 259.24%, down 18676.0% from the prior year.
- Return on Capital Employed slipped to 451.05% in Q4 2023, from 153.51% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 46.0% in Q1 2019 to a low of 451.05% in Q4 2023.
- A 5-year average of 122.8% and a median of 91.17% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2021 — Return on Capital Employed jumped 20181 bps — and 2023, when it sank 35027 bps.
- Tracing OGEN's Return on Capital Employed over 5 years: stood at 79.98% in 2019, then sank by 144 bps to 195.33% in 2020, then soared by 71 bps to 55.89% in 2021, then slumped by 80 bps to 100.78% in 2022, then slumped by 348 bps to 451.05% in 2023.
- The last three Return on Capital Employed figures came in at 451.05% (Q4 2023), 153.51% (Q3 2023), and 133.47% (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Oragenics | 2.31 Mn | 2.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -451.05% |
| Sep 30, 2023 | -153.51% |
| Jun 30, 2023 | -133.47% |
| Mar 31, 2023 | -109.02% |
| Dec 31, 2022 | -100.78% |
| Sep 30, 2022 | -84.20% |
| Jun 30, 2022 | -72.59% |
| Mar 31, 2022 | -61.73% |
| Dec 31, 2021 | -55.89% |
| Sep 30, 2021 | -58.17% |
| Jun 30, 2021 | -53.03% |
| Mar 31, 2021 | -98.13% |
| Dec 31, 2020 | -195.33% |
| Sep 30, 2020 | -259.99% |
| Jun 30, 2020 | -213.48% |
| Mar 31, 2020 | -113.33% |
| Dec 31, 2019 | -79.98% |
| Sep 30, 2019 | -65.28% |
| Jun 30, 2019 | -51.01% |
| Mar 31, 2019 | -46.00% |